Literature DB >> 31124743

Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.

Daniel E Velasquez1, Baoming Jiang1.   

Abstract

Non-replicating parenteral rotavirus (RV) vaccine candidates are in development in an attempt to overcome the lower efficacy and effectiveness of oral RV vaccines in low-income countries. One of the leading candidates is a truncated recombinant VP8* protein, expressed in Escherichia coli from original sequences of the prototype RV genotypes P[8], P[4], or P[6] isolated before 1983. Since VP8* is highly variable, it was considered useful to examine the evolutionary changes of RV strains reported worldwide over time in relation to the three P2-VP8 vaccine strains. Here, we retrieved from the GenBank 6,366 RV VP8* gene sequences of P[8], P[4], or P[6] strains isolated between 1974 and 2017, in 77 countries, and compared them with those of the three P2-VP8 vaccine strains: Wa (USA, 1974, G1P[8]), DS-1 (USA, 1976, G2P[4]), and 1076 (Sweden, 1983, G2P[6]). Phylogenetic analysis showed that 94.9% (4,328/4,560), 99.8% (1,141/1,143), and 100% (663/663) of the P[8], P[4], and P[6] strains, respectively, reported globally between 1974 and 2018 belong to non-vaccine lineages. These P[8], P[4], and P[6] RV strains have a mean of 9%, 5%, and 6% amino acid difference from the corresponding vaccine strains. Additionally, in the USA, the mean percentage difference between all the P[8] RV strains and the original Wa strain increased over time: 4% (during 1974-1980), 5% (1988-1991), and 9% (2005-2013). Our analysis substantiated high evolutionary changes in VP8* of the P[8], P[4], and P[6] major RV strains and their increasing variations from the candidate subunit vaccine strains over time. These findings may have implications for the development of new RV vaccines.

Entities:  

Keywords:  P type; Rotavirus; VP4; VP8* protein; diarrhea; diversity; evolution; genotype; protection; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31124743      PMCID: PMC6930099          DOI: 10.1080/21645515.2019.1619400

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  39 in total

1.  Whole genome analyses of G1P[8] rotavirus strains from vaccinated and non-vaccinated South African children presenting with diarrhea.

Authors:  Nonkululeko B Magagula; Mathew D Esona; Martin M Nyaga; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Mapaseka L Seheri; A Duncan Steele; David E Wentworth; M Jeffrey Mphahlele
Journal:  J Med Virol       Date:  2014-05-20       Impact factor: 2.327

2.  Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.

Authors:  Umesh D Parashar; Hope Johnson; A Duncan Steele; Jacqueline E Tate
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

3.  Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.

Authors:  Vesna Blazevic; Suvi Lappalainen; Kirsi Nurminen; Leena Huhti; Timo Vesikari
Journal:  Vaccine       Date:  2011-08-18       Impact factor: 3.641

4.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Authors:  K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

5.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  George E Armah; Samba O Sow; Robert F Breiman; Michael J Dallas; Milagritos D Tapia; Daniel R Feikin; Fred N Binka; A Duncan Steele; Kayla F Laserson; Nana A Ansah; Myron M Levine; Kristen Lewis; Michele L Coia; Margaret Attah-Poku; Joel Ojwando; Stephen B Rivers; John C Victor; Geoffrey Nyambane; Abraham Hodgson; Florian Schödel; Max Ciarlet; Kathleen M Neuzil
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

6.  Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life.

Authors:  Nita Bhandari; Temsunaro Rongsen-Chandola; Ashish Bavdekar; Jacob John; Kalpana Antony; Sunita Taneja; Nidhi Goyal; Anand Kawade; Gagandeep Kang; Sudeep Singh Rathore; Sanjay Juvekar; Jayaprakash Muliyil; Alok Arya; Hanif Shaikh; Vinod Abraham; Sudhanshu Vrati; Michael Proschan; Robert Kohberger; Georges Thiry; Roger Glass; Harry B Greenberg; George Curlin; Krishna Mohan; G V J A Harshavardhan; Sai Prasad; T S Rao; John Boslego; Maharaj Kishan Bhan
Journal:  Vaccine       Date:  2014-08-11       Impact factor: 3.641

7.  Effect of human rotavirus vaccine on severe diarrhea in African infants.

Authors:  Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

8.  Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013.

Authors:  Michael D Bowen; Slavica Mijatovic-Rustempasic; Mathew D Esona; Elizabeth N Teel; Rashi Gautam; Michele Sturgeon; Parvin H Azimi; Carol J Baker; David I Bernstein; Julie A Boom; James Chappell; Stephanie Donauer; Kathryn M Edwards; Janet A Englund; Natasha B Halasa; Christopher J Harrison; Samantha H Johnston; Eileen J Klein; Monica M McNeal; Mary E Moffatt; Marcia A Rench; Leila C Sahni; Rangaraj Selvarangan; Mary A Staat; Peter G Szilagyi; Geoffrey A Weinberg; Mary E Wikswo; Umesh D Parashar; Daniel C Payne
Journal:  J Infect Dis       Date:  2016-06-14       Impact factor: 5.226

Review 9.  Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.

Authors:  E Clarke; U Desselberger
Journal:  Mucosal Immunol       Date:  2014-12-03       Impact factor: 7.313

Review 10.  Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors.

Authors:  Ulrich Desselberger
Journal:  Pathogens       Date:  2017-12-12
View more
  3 in total

1.  VP4 Is a Determinant of Alpha-Defensin Modulation of Rotaviral Infection.

Authors:  Ciara T Hu; Karina Diaz; Linda C Yang; Anjali Sharma; Harry B Greenberg; Jason G Smith
Journal:  J Virol       Date:  2022-03-14       Impact factor: 6.549

Review 2.  The Rotavirus Vaccine Landscape, an Update.

Authors:  Roberto Cárcamo-Calvo; Carlos Muñoz; Javier Buesa; Jesús Rodríguez-Díaz; Roberto Gozalbo-Rovira
Journal:  Pathogens       Date:  2021-04-26

3.  Novel antigen panel for modern broad-spectrum recombinant rotavirus A vaccine.

Authors:  Olga A Kondakova; Peter A Ivanov; Oleg A Baranov; Ekaterina M Ryabchevskaya; Marina V Arkhipenko; Eugene V Skurat; Ekaterina A Evtushenko; Nikolai A Nikitin; Olga V Karpova
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.